BioCentury | Oct 3, 2016
Company News

ImmunoGen cancer news

...320 and seek to partner its non-core B cell lymphoma programs IMGN529 and coltuximab ravtansine ( SAR3419...
BioCentury | Apr 25, 2015
Company News

ImmunoGen regains rights to DLBCL candidate

...ImmunoGen Inc. (NASDAQ:IMGN) said it regained rights to coltuximab ravtansine ( SAR3419 ) from Sanofi (Euronext:SAN; NYSE:SNY...
...earnings call, President and CEO Daniel Junius said ImmunoGen may perform a head-to-head comparison of coltuximab ravtansine...
BioCentury | Jun 9, 2014
Finance

Highlights of weekly biotech stock moves

...Co. (NYSE:BMY). Clinical milestones ImmunoGen Inc. (NASDAQ:IMGN) was up $0.20 to $12.02 last week after SAR3419...
...meeting the primary endpoint of an ORR of 20% or greater. ImmunoGen is developing SAR3419...
BioCentury | Jun 9, 2014
Clinical News

Coltuximab ravtansine: Phase II data

...of the open-label, international Phase II STARLYTE trial showed that once-weekly 55 mg/m 2 IV SAR3419...
...14 evaluable patients with primary refractory disease (cancer that had not responded to first-line treatment), SAR3419...
...MabThera elsewhere. ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Coltuximab ravtansine ( SAR3419...
BioCentury | Jun 3, 2014
Clinical News

SAR3419 meets in Phase II trial in DLBCL

...IV SAR3419 from ImmunoGen Inc. (NASDAQ:IMGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) led to an overall response...
...relapsed/refractory CD19-positive DLBCL in the per protocol population. Patients in the trial are receiving once-weekly SAR3419...
...were presented at the American Society of Clinical Oncology meeting in Chicago. ImmunoGen is developing SAR3419...
BioCentury | May 5, 2014
Clinical News

Coltuximab ravtansine: Development discontinued

...Sanofi disclosed in its 1Q14 earnings that it discontinued development of SAR3419 in ALL. The compound...
...Phase II testing in patients with relapsed or refractory ALL. Sanofi plans to continue developing SAR3419...
...4, 2003). ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Coltuximab ravtansine ( SAR3419...
BioCentury | Jan 13, 2014
Clinical News

Coltuximab ravtansine: Phase II data

...standard treatment in an open-label, European Phase II trial showed that 55 mg/m 2 IV SAR3419...
...in patients with primary refractory disease (n=26). OS and PFS data are not yet mature. SAR3419...
...MabThera elsewhere. ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Coltuximab ravtansine ( SAR3419...
BioCentury | May 28, 2012
Clinical News

SAR3419: Phase I data

...open-label, French Phase I trial showed that an optimized regimen of 55 mg/m 2 IV SAR3419...
...extended the Phase I trial with the optimized dosing cohort after data showed that once-weekly SAR3419...
...adverse events and antibody-drug conjugate (ADC) accumulation after 4 weeks. The optimized dosing regimen of SAR3419...
BioCentury | Oct 31, 2011
Clinical News

SAR3419: Phase II started

...Sanofi began a Phase II trial evaluating SAR3419. The trial start triggers a $3 million milestone...
...BioCentury, Aug. 4, 2003). ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: SAR3419...
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

...into Phase II trials to treat non-Hodgkin's lymphoma (NHL) next year. The deal also included SAR3419...
...earlier in development that have yet to be disclosed (see BioCentury, Aug. 4, 2003) . SAR3419...
...2003 Aventis S.A., now sanofi-aventis Group (Euronext:SAN; NYSE:SNY) Deal to discover and develop anti-cancer therapeutics SAR3419...
Items per page:
1 - 10 of 13